Abstract

Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer. The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use. A search of literature published in the last several years in the Pubmed and MedLine databases was performed. The obtained data was analyzed, sensitivity, specificity, positive and negative prognostic value were determined. The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case. The clinical role of urine biomarkers in observation of patients with nonmuscle invasive bladder cancer remains uncertain. Assays approved by the U.S. Food and Drug Administration do not demonstrate desired sensitivity and specificity which leads to their limited use. Currently, commercial assays of urine biomarkers are not sufficiently studied which predetermines further search for the optimal method of early diagnosis of bladder cancer. Multicenter clinical studies will allow to determine the place of each molecular biomarker in clinical practice.

Highlights

  • Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer

  • The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use

  • The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case

Read more

Summary

Introduction

ĐŠĐžŃŃ‚ĐŸŃĐșĐŸĐżĐžŃ, ĐŸĐ±Ń‰Đ”ĐżŃ€ĐžĐœŃŃ‚Đ°Ń ĐČ ĐșачДстĐČĐ” Â«Đ·ĐŸĐ»ĐŸŃ‚ĐŸĐłĐŸ ŃŃ‚Đ°ĐœĐŽĐ°Ń€Ń‚Đ°Â» ĐŸĐ±ĐœĐ°Ń€ŃƒĐ¶Đ”ĐœĐžŃ РМП, яĐČĐ»ŃĐ”Ń‚ŃŃ ĐžĐœĐČĐ°Đ·ĐžĐČĐœĐŸĐč ĐżŃ€ĐŸŃ†Đ”ĐŽŃƒŃ€ĐŸĐč, ŃĐŸĐżŃ€ŃĐ¶Đ”ĐœĐœĐŸĐč с росĐșĐŸĐŒ разĐČотоя ĐžĐœŃ„Đ”ĐșŃ†ĐžĐŸĐœĐœŃ‹Ń… ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč, ĐČ Ń‚ĐŸ ĐČŃ€Đ”ĐŒŃ ĐșĐ°Đș Ń†ĐžŃ‚ĐŸĐ»ĐŸĐłĐžŃ‡Đ”ŃĐșĐŸĐ” ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐ” ĐŒĐŸŃ‡Đž ĐžĐŒĐ”Đ”Ń‚ ĐČŃ‹ŃĐŸĐșую чуĐČстĐČĐžŃ‚Đ”Đ»ŃŒĐœĐŸŃŃ‚ŃŒ (84 %) Đ»ĐžŃˆŃŒ про ĐŸĐżŃƒŃ…ĐŸĐ»ŃŃ… ĐČŃ‹ŃĐŸĐșĐŸĐč ŃŃ‚Đ”ĐżĐ”ĐœĐž Đ·Đ»ĐŸĐșачДстĐČĐ”ĐœĐœĐŸŃŃ‚Đž. ĐĄ ŃƒŃ‡Đ”Ń‚ĐŸĐŒ ĐœĐžĐ·ĐșĐŸĐč чуĐČстĐČĐžŃ‚Đ”Đ»ŃŒĐœĐŸŃŃ‚Đž Ń†ĐžŃ‚ĐŸĐ»ĐŸĐłĐžŃ‡Đ”ŃĐșĐŸĐłĐŸ ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ ĐŒĐŸŃ‡Đž, Đ° таĐșжД ĐČŃ€Đ”ĐŒĐ”ĐœĐœŃ‹Ń… Đž ĐžĐœĐŸĐłĐŽĐ° Ń„ĐžĐœĐ°ĐœŃĐŸĐČых ĐŸĐłŃ€Đ°ĐœĐžŃ‡Đ”ĐœĐžĐč, сĐČŃĐ·Đ°ĐœĐœŃ‹Ń… с ĐżŃ€ĐŸĐČĐ”ĐŽĐ”ĐœĐžĐ”ĐŒ Ń†ĐžŃŃ‚ĐŸŃĐșĐŸĐżĐžĐž, былО Ń€Đ°Đ·Ń€Đ°Đ±ĐŸŃ‚Đ°ĐœŃ‹ Đž ĐČĐœĐ”ĐŽŃ€Đ”ĐœŃ‹ ĐČ ĐșĐ»ĐžĐœĐžŃ‡Đ”ŃĐșую праĐșтоĐșу ĐŒĐœĐŸĐłĐŸŃ‡ĐžŃĐ»Đ”ĐœĐœŃ‹Đ” Đ±ĐžĐŸĐŒĐ°Ń€ĐșДры ĐČ ĐŒĐŸŃ‡Đ”. ĐŁ ряЮа Đ±ĐžĐŸĐŒĐ°Ń€ĐșĐ”Ń€ĐŸĐČ, ĐŸĐŽĐŸĐ±Ń€Đ”ĐœĐœŃ‹Ń… УпраĐČĐ»Đ”ĐœĐžĐ”ĐŒ ĐżĐŸ ŃĐ°ĐœĐžŃ‚Đ°Ń€ĐœĐŸĐŒŃƒ ĐœĐ°ĐŽĐ·ĐŸŃ€Ńƒ Đ·Đ° ĐșачДстĐČĐŸĐŒ пОщДĐČых ĐżŃ€ĐŸĐŽŃƒĐșŃ‚ĐŸĐČ Đž ĐŒĐ”ĐŽĐžĐșĐ°ĐŒĐ”ĐœŃ‚ĐŸĐČ ĐĄĐšĐ, ĐœĐ” ĐŸĐżŃ€Đ”ĐŽĐ”Đ»Đ”ĐœĐ° ŃŃ‚Đ”ĐżĐ”ĐœŃŒ ĐșĐ»ĐžĐœĐžŃ‡Đ”ŃĐșĐŸĐč Đ·ĐœĐ°Ń‡ĐžĐŒĐŸŃŃ‚Đž, Ń‡Ń‚ĐŸ ĐŸĐłŃ€Đ°ĐœĐžŃ‡ĐžĐČаДт ох ĐžŃĐżĐŸĐ»ŃŒĐ·ĐŸĐČĐ°ĐœĐžĐ”, ĐŸŃĐŸĐ±Đ”ĐœĐœĐŸ про ĐœĐ°Đ±Đ»ŃŽĐŽĐ”ĐœĐžĐž Đ·Đ° ĐżĐ°Ń†ĐžĐ”ĐœŃ‚Đ°ĐŒĐž с росĐșĐŸĐŒ ĐżŃ€ĐŸĐłŃ€Đ”ŃŃĐžŃ€ĐŸĐČĐ°ĐœĐžŃ Đž / ОлО рДцОЎОĐČĐ° РМП [4].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call